In the management of diabetes, postprandial glycemia (PPG) is usually targeted 2 h after the start of meal. Recent evidences, however, suggest that the value of glycemia at 1 h during an oral glucose tolerance test (OGTT) is a stronger predictor for developing diabetes than the value at 2 h and that it is an independent risk factor for cardiovascular disease. Studies in cells, animals, and humans suggest that 1-h high glucose is a sufficient stimulus for increasing several cardiovascular risk factors, such as inflammation, thrombosis, and endothelial dysfunction, with oxidative stress generation as the possible pathogenetic factor. One-hour glucose might be more dangerous than that at 2 h simply because glycemia is higher at 1 h, during an OGTT and postmeal. The new drugs, able to target better 1 h glycemia and the new noninvasive technologies for glucose monitoring, nowadays may help to change the therapeutic paradigm of targeting PPG at 2 h.
Get full access to this article
View all access options for this article.
References
1.
International Diabetes Federation: Guideline for Management of Postmeal Glucose. 2011. www.idf.org/sites/default/files/postmeal%20glucose%20guidelines.pdf (accessed January15, 2017).
2.
CerielloA, HanefeldM, LeiterL, et al.: Postprandial glucose regulation and diabetic complications. Arch Intern Med, 2004; 164:2090–2095.
3.
StandlE, SchnellO, CerielloA: Postprandial hyperglycemia and glycemic variability: should we care?. Diabetes Care, 2011; 34(Suppl 2):S120–S127.
4.
The Expert Committee on the Diagnosis and Classification of Diabetes Mellitus: Report of the expert committee on the diagnosis and classification of diabetes mellitus. Diabetes Care, 1997; 20:1183–1197.
5.
American Diabetes Association: Standards of medical care in diabetes—2017. Diabetes Care, 2017; 40(Suppl 1):S4–S5.
6.
UnwinN, ShawJ, ZimmetP, AlbertiKG: Impaired glucose tolerance and impaired fasting glycaemia: the current status on definition and intervention. Diabet Med, 2002; 19:708–723.
7.
Abdul-GhaniMA, WilliamsK, DeFronzoRA, SternM: What is the best predictor of future Type 2 diabetes?. Diabetes Care, 2007; 30:1544–1548.
8.
OhTJ, LimS, KimKM, et al.: One-hour postload plasma glucose concentration in people with normal glucose homeostasis predicts future diabetes mellitus: a 12-year community-based cohort study. Clin Endocrinol (Oxf), 2017; 86:513–519.
9.
JagannathanR, SevickMA, LiH, et al.: Elevated 1-hour plasma glucose levels are associated with dysglycemia, impaired beta-cell function, and insulin sensitivity: a pilot study from a real world health care setting. Endocrine, 2016; 52:172–175.
10.
WuX, ChenH, WangY, LiH: The relationship between coronary risk factors and elevated 1-h postload plasma glucose levels in patients with established coronary heart disease. Clin Endocrinol (Oxf), 2013; 78:67–72.
11.
PerticoneF, SciacquaA, PerticoneM, et al.: Serum uric acid and 1-h postload glucose in essential hypertension. Diabetes Care, 2012; 35:153–157.
12.
O'LearyDH, PolakJF, KronmalRA, et al.: Cardiovascular Health Study Collaborative Research Group. Carotid-artery intima and media thickness as a risk factor for myocardial infarction and stroke in older adults. N Engl J Med, 1999; 340:14–22.
13.
SciacquaA, MaioR, MiceliS, et al.: Association between one-hour post-load plasma glucose levels and vascular stiffness in essential hypertension. PLoS One, 2012; 7:e44470.
14.
FiorentinoTV, SestiF, AndreozziF, et al.: One-hour post-load hyperglycemia combined with HbA1c identifies pre-diabetic individuals with a higher cardio-metabolic risk burden. Atherosclerosis, 2016; 253:61–69.
15.
TsuboiA, ItoC, FujikawaR, et al.: Association between the postprandial glucose levels and arterial stiffness measured according to the cardio-ankle vascular index in non-diabetic subjects. Intern Med, 2015; 54:1961–1969.
16.
Temelkova-KurktschievTS, KoehlerC, HenkelE, et al.: Postchallenge plasma glucose and glycemic spikes are more strongly associated with atherosclerosis than fasting glucose or HbA1c level. Diabetes Care, 2000; 23:1830–1834.
17.
EspositoK, CiotolaM, CarleoD, et al.: Post-meal glucose peaks at home associate with carotid intima-media thickness in Type 2 diabetes. J Clin Endocrinol Metab, 2008; 93:1345–1350.
18.
SciacquaA, MiceliS, CarulloG, et al.: One-hour postload plasma glucose levels and left ventricular mass in hypertensive patients. Diabetes Care, 2011; 34:1406–1411.
19.
SciacquaA, MiceliS, GrecoL, et al.: One-hour postload plasma glucose levels and diastolic function in hypertensive patients. Diabetes Care, 2011; 34:2291–2296.
20.
BergmanM, ChetritA, RothJ, DanknerR: One-hour post-load plasma glucose level during the OGTT predicts mortality: observations from the Israel study of glucose intolerance, obesity and hypertension. Diabet Med, 2016; 33:1060–1066.
21.
VaccaroO, RuthKJ, StamlerJ: Relationship of postload plasma glucose to mortality with 19-yr follow-up. Comparison of one versus two plasma glucose measurements in the Chicago Peoples Gas Company Study. Diabetes Care, 1992; 15:1328–1334.
22.
CersosimoE, DeFronzoRA: Insulin resistance and endothelial dysfunction: the road map to cardiovascular diseases. Diabetes Metab Res Rev, 2006; 22:423–436.
23.
BagiZ, TothE, KollerA, KaleyG: Microvascular dysfunction after transient high glucose is caused by superoxide-dependent reduction in the bioavailability of NO and BH(4). Am J Physiol Heart Circ Physiol, 2004; 287:H626–H633.
24.
BohlenHG, LashJM: Topical hyperglycemia rapidly suppresses EDRF-mediated vasodilation of normal rat arterioles. Am J Physiol, 1993; 265(1 Pt 2):H219–H225.
25.
CerielloA, EspositoK, TestaR, et al.: The possible protective role of glucagon-like peptide 1 on endothelium during the meal and evidence for an “endothelial resistance” to glucagon-like peptide 1 in diabetes. Diabetes Care, 2011; 34:697–702.
26.
CerielloA: Hyperglycaemia and the vessel wall: the pathophysiological aspects on the atherosclerotic burden in patients with diabetes. Eur J Cardiovasc Prev Rehabil, 2010; 17(Suppl 1):S15–S19.
27.
CerielloA, TestaR, GenoveseS: Clinical implications of oxidative stress and potential role of natural antioxidants in diabetic vascular complications. Nutr Metab Cardiovasc Dis, 2016; 26:285–292.
28.
GiaccoF, DuX, CarratúA, et al.: GLP-1 cleavage product reverses persistent ROS generation after transient hyperglycemia by disrupting an ROS-generating feedback loop. Diabetes, 2015; 64:3273–3284.
29.
MonnierL, ColetteC, DunseathGJ, OwensDR: The loss of postprandial glycemic control precedes stepwise deterioration of fasting with worsening diabetes. Diabetes Care, 2007; 30:263–269.
30.
MonnierL, ColetteC, DejagerS, OwensD: Magnitude of the dawn phenomenon and its impact on the overall glucose exposure in Type 2 diabetes: is this of concern?. Diabetes Care, 2013; 36:4057–4062.
31.
KawanoH, MotoyamaT, HirashimaO, et al.: Hyperglycemia rapidly suppresses flow-mediated endothelium-dependent vasodilation of brachial artery. J Am Coll Cardiol, 1999; 34:146–154.
32.
CerielloA, EspositoK, PiconiL, et al.: Glucose “peak” and glucose “spike”: impact on endothelial function and oxidative stress. Diabetes Res Clin Pract, 2008; 82:262–267.
33.
BibraHV, SiegmundT, CerielloA, et al.: Optimized postprandial glucose control is associated with improved cardiac/vascular function—comparison of three insulin regimens in well-controlled Type 2 diabetes. Horm Metab Res, 2009; 41:109–115.
34.
BeisswengerPJ, BrownWV, CerielloA, et al.: Meal-induced increases in C-reactive protein, interleukin-6 and tumour necrosis factor α are attenuated by prandial + basal insulin in patients with Type 2 diabetes. Diabet Med, 2011; 28:1088–1095.
35.
CerielloA, GiacomelloR, StelG, et al.: Hyperglycemia-induced thrombin formation in diabetes. The possible role of oxidative stress. Diabetes, 1995; 44:924–928.
36.
CerielloA, QuagliaroL, CatoneB, et al.: Role of hyperglycemia in nitrotyrosine postprandial generation. Diabetes Care, 2002; 25:1439–1443.
37.
YanD, ZhaoY, GaoX, ZhouY: Acute intravenous glucose load impairs early insulin secretion and insulin content in islet β cells in mice. Life Sci, 2016; 144:148–155.
38.
FernerRE, AshworthL, TronierB, AlbertiKG: Effects of short-term hyperglycemia on insulin secretion in normal humans. Am J Physiol, 1986; 250(6 Pt 1):E655–E661.
39.
BreretonMF, RohmM, ShimomuraK, et al.: Hyperglycaemia induces metabolic dysfunction and glycogen accumulation in pancreatic β-cells. Nat Commun, 2016; 7:13496.
40.
MeierJJ, BallerB, MengeBA, et al.: Excess glycaemic excursions after an oral glucose tolerance test compared with a mixed meal challenge and self-measured home glucose profiles: is the OGTT a valid predictor of postprandial hyperglycaemia and vice versa?. Diabetes Obes Metab, 2009; 11:213–222.
41.
CavalotF, PagliarinoA, ValleM, et al.: Postprandial blood glucose predicts cardiovascular events and all-cause mortality in Type 2 diabetes in a 14-year follow-up: lessons from the San Luigi Gonzaga Diabetes Study. Diabetes Care, 2011; 34:2237–2243.
42.
TakaoT, SukaM, YanagisawaH, IwamotoY: The impact of postprandial hyperglycemia at clinic visits on the incidence of cardiovascular events and all-cause mortality in patients with Type 2 diabetes. J Diabetes Investig, 2016 [Epub ahead of print]; DOI: 10.1111/jdi.12610
43.
CerielloA: Point: postprandial glucose levels are a clinically important treatment target. Diabetes Care, 2010; 33:1905–1907.
44.
The American Association of Clinical Endocrinologists: AACE/ACE Comprehensive Type 2 Diabetes Management Algorithm. 2017. www.aace.com/publications/algorithm (accessed January19, 2017).
45.
MaratheCS, HorowitzM, TrahairLG, et al.: Relationships of early and late glycemic responses with gastric emptying during an oral glucose tolerance test. J Clin Endocrinol Metab, 2015; 100:3565–3571.
46.
OwensDR, MonnierL, BolliGB: Differential effects of GLP-1 receptor agonists on components of dysglycaemia in individuals with Type 2 diabetes mellitus. Diabetes Metab, 2013; 39:485–496.
47.
European Medicines Agency: Summary of Product Characteristics Fiasp. 2017. www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/004046/WC500220890.pdf (accessed February21, 2017).
48.
Russell-JonesD, BodeBW, De BlockC, et al.: Fast-acting insulin aspart improves glycemic control in basal-bolus treatment for Type 1 diabetes: results of a 26-week multicenter, active-controlled, treat-to-target, randomized, parallel-group trial (onset 1). Diabetes Care, 2017 [Epub ahead of print]; DOI: 10.2337/dc16-1771
49.
BoweringK, CaseC, HarveyJ, et al.: Faster aspart versus insulin aspart as part of a basal-bolus regimen in inadequately controlled Type 2 diabetes: the onset 2 trial. Diabetes Care, 2017 [Epub head of print]; DOI: 10.2337/dc16-1770
50.
Adocia Press Release of 27th of January 2017. www.adocia.fr/WP/wp-content/uploads/2017/01/170127-Adocia-BC-Lispro-EN-VF.pdf (accessed on February21, 2017).
51.
HortensiusJ, KarsMC, WierengaWS, et al.: Perspectives of patients with Type 1 or insulin treated Type 2 diabetes on self-monitoring of blood glucose: a qualitative study. BMC Public Health, 2012; 12:167–177.
HaakT, HanaireH, AjjanR, et al.: Flash glucose-sensing technology as a replacement for blood glucose monitoring for the management of insulin-treated Type 2 diabetes: a multicenter, open-label randomized controlled trial. Diabetes Ther, 2017; 8:573–586.
